STAT Plus: Pharmalittle: Bristol cancer drug is approved in China; Teva gets a headache over migraine trial flops

In a big win for Bristol-Myers Squibb, the Chinese Food and Drug Administration approved its Opdvid immunotherapy for second-line treatment of non-small cell lung cancer.

More From BioPortfolio on "STAT Plus: Pharmalittle: Bristol cancer drug is approved in China; Teva gets a headache over migraine trial flops"